Myelodysplasia
1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
SandozDeferasirox
Clinical Trials (1)
Total enrollment: 39 patients across 1 trials
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
Start: Feb 2018Est. completion: Oct 202439 patients
Phase 2Completed
Related Jobs
Cell Therapy Account Manager, Raleigh/Durham
Field - United States - US; Raleigh - NC - US; Durham - NC - US
2w ago
$171K - $208K/yr
Cell Therapy Account Manager, Louisville
Field - United States - US; Louisville - KY - US
2w ago
$171K - $208K/yr
Cell Therapy Account Manager, Portland
Field - United States - US; Portland - OR - US
2w ago
$171K - $208K/yr
Cell Therapy Account Manager, Cincinnati
Field - United States - US; Cincinnati - OH - US
2w ago
$171K - $208K/yr
Cell Therapy Account Manager, Sacramento
Field - United States - US; Sacramento - CA - US
2w ago
$171K - $208K/yr
Cell Therapy Account Manager, Jacksonville, FL
Field - United States - US; Jacksonville - FL - US
2w ago
$171K - $208K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.